KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 31.35%.

  • Supernus Pharmaceuticals' EBIT Margin fell 546000.0% to 31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.42%, marking a year-over-year decrease of 145100.0%. This contributed to the annual value of 12.34% for FY2024, which is 132100.0% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBIT Margin of 31.35% as of Q3 2025, which was down 546000.0% from 7.34% recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBIT Margin peaked at 24.14% during Q2 2021, and registered a low of 31.35% during Q3 2025.
  • Moreover, its 5-year median value for EBIT Margin was 5.29% (2023), whereas its average is 5.19%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBIT Margin soared by 263800bps in 2024, and later crashed by -546000bps in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' EBIT Margin stood at 3.83% in 2021, then soared by 435bps to 20.52% in 2022, then plummeted by -103bps to 0.61% in 2023, then skyrocketed by 2128bps to 12.29% in 2024, then tumbled by -355bps to 31.35% in 2025.
  • Its EBIT Margin stands at 31.35% for Q3 2025, versus 7.34% for Q2 2025 and 6.85% for Q1 2025.